395 related articles for article (PubMed ID: 16707462)
1. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM; Batey MA; Zhao Y; Jenkins H; Richardson CJ; Cano C; Tavecchio M; Barbeau J; Bardos J; Cornell L; Griffin RJ; Menear K; Slade A; Thommes P; Martin NM; Newell DR; Smith GC; Curtin NJ
Mol Cancer Ther; 2012 Aug; 11(8):1789-98. PubMed ID: 22576130
[TBL] [Abstract][Full Text] [Related]
3. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
5. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
[TBL] [Abstract][Full Text] [Related]
6. DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
Kopa P; Macieja A; Pastwa E; Majsterek I; Poplawski T
Mol Biol Rep; 2021 Jan; 48(1):709-720. PubMed ID: 33389482
[TBL] [Abstract][Full Text] [Related]
7. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ
Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086
[TBL] [Abstract][Full Text] [Related]
8. Radio-sensitization of human leukaemic MOLT-4 cells by DNA-dependent protein kinase inhibitor, NU7441.
Tichy A; Durisova K; Salovska B; Pejchal J; Zarybnicka L; Vavrova J; Dye NA; Sinkorova Z
Radiat Environ Biophys; 2014 Mar; 53(1):83-92. PubMed ID: 24100951
[TBL] [Abstract][Full Text] [Related]
9. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
Willmore E; de Caux S; Sunter NJ; Tilby MJ; Jackson GH; Austin CA; Durkacz BW
Blood; 2004 Jun; 103(12):4659-65. PubMed ID: 15010369
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Batey MA; Zhao Y; Kyle S; Richardson C; Slade A; Martin NM; Lau A; Newell DR; Curtin NJ
Mol Cancer Ther; 2013 Jun; 12(6):959-67. PubMed ID: 23512991
[TBL] [Abstract][Full Text] [Related]
11. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair.
Dong J; Ren Y; Zhang T; Wang Z; Ling CC; Li GC; He F; Wang C; Wen B
Oncol Rep; 2018 Mar; 39(3):912-920. PubMed ID: 29344644
[TBL] [Abstract][Full Text] [Related]
13. NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L; Shang ZF; Hsu FM; Zhang Z; Tumati V; Lin YF; Chen BP; Saha D
Oncotarget; 2015 Feb; 6(6):3848-60. PubMed ID: 25714019
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
15. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.
Gustafsson AS; Abramenkovs A; Stenerlöw B
Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720
[TBL] [Abstract][Full Text] [Related]
16. Changes in the response of MCF-7 cells to ionizing radiation after the combination of ATM and DNA-PK inhibition.
Ćmielová J; Havelek R; Vávrová J; Řezáčová M
Med Oncol; 2015 May; 32(5):138. PubMed ID: 25801233
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin.
Alikarami F; Safa M; Faranoush M; Hayat P; Kazemi A
Biomed Pharmacother; 2017 Oct; 94():1077-1093. PubMed ID: 28821159
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA double strand break repair with hyperthermia and DNA-PKcs inhibition to enhance the effect of radiation treatment.
van Oorschot B; Granata G; Di Franco S; Ten Cate R; Rodermond HM; Todaro M; Medema JP; Franken NA
Oncotarget; 2016 Oct; 7(40):65504-65513. PubMed ID: 27602767
[TBL] [Abstract][Full Text] [Related]
19. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L; Tumati V; Tseng SF; Hsu FM; Kim DN; Hong D; Hsieh JT; Jacobs C; Kapur P; Saha D
Neoplasia; 2012 Dec; 14(12):1203-12. PubMed ID: 23308052
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
